Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.…
Ironwood Pharmaceuticals Inc (IRWD) (Q3 2026) Earnings Call Highlights: Record LINZESS Sales ...
Ironwood Pharmaceuticals (NASDAQ: IRWD) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 100 employees.
The shares were at 4.700 USD on 20 November 2026, up 144.8% over 52 weeks. Its 52-week range is 2.310 USD to 5.780 USD: the price is 18.7% below the high and 103.5% above the low.
At a market capitalisation of 778.09M USD, it trades at 5.2 times trailing earnings and 3.0 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.5, a discount of 79% for IRWD.
Ironwood Pharmaceuticals reports return on equity of -9.2%, an operating margin of 62.9% and revenue up 9.0% year over year.
Its debt exceeds its cash by 249.83M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 4 analysts cover the stock; their mean price target of 6.175 USD is 31.4% above the current price. The next earnings report is expected on 24 February 2027.